TG Therapeutics TGTX Total debt
Total debt at other companies
Other financials
Where this comes from
Calculated from TG Therapeutics’s reported figures.
Plus components not separately reported this period.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's total debt?
- TG Therapeutics (TGTX) reported total debt of $753.56M in Q1 2026.
- How has TG Therapeutics's total debt changed year-over-year?
- TG Therapeutics's total debt increased by 197.0% year-over-year, from $253.71M to $753.56M.
- What is the long-term trend for TG Therapeutics's total debt?
- Over 5 years (2020 to 2025), TG Therapeutics's total debt has grown at a 43.3% compound annual growth rate (CAGR), from $41.98M to $253.71M.
- What does total debt mean?
- The total amount of money the company owes to banks, bondholders, and other lenders.
- How do you interpret total debt?
- An increase in total debt suggests higher financial leverage and increased interest expense, which may heighten insolvency risk if not matched by growth in cash flow. A decrease indicates deleveraging, which typically improves the balance sheet's resilience and reduces interest burden.
- How does total debt compare across companies?
- Peers in the biotechnology sector often maintain low total debt levels during early-stage development, while mature firms may carry higher debt loads to fund commercialization and M&A activities.